{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T05:53:28Z","timestamp":1767851608739,"version":"3.49.0"},"reference-count":53,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2012,4,24]],"date-time":"2012-04-24T00:00:00Z","timestamp":1335225600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Asia-Pac J Clncl Oncology"],"published-print":{"date-parts":[[2012,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Sunitinib is the gold standard of care for patients with metastatic renal cell carcinoma, demonstrating an overall survival benefit of over 2\u2003years in a pivotal phase 3 trial of 750 patients. While sunitinib is generally well tolerated with most adverse events, manifesting as mild to moderate in severity and manageability, it has a distinctive adverse event profile that benefits from careful monitoring during treatment. As sunitinib gains widespread use across the globe, best practices are being developed for specific patient groups. This review will focus on the current clinical trial data in Asian populations and on the mechanism, incidence and management of selected sunitinib\u2010related adverse events, including hand\u2010foot syndrome, hypertension, proteinuria, cardiac toxicities, myelosupression, fatigue\/asthenia, hypothyroidism, diarrhea and hepatotoxicity. Taken together, the developing body of literature reviewed here demonstrates that sunitinib is well tolerated in Asian patients and provides efficacy that is similar, if not superior, to other patient groups. Asian patients, like all patients, should begin treatment of sunitinib at 50\u2003mg on Schedule 4\/2 (4\u2003weeks on treatment\/2\u2003weeks off). Prophylactic measures, good communication between patient and health\u2010care providers, and early, aggressive intervention at the development of adverse events can limit the dose reductions required and maximize both patients' response to treatment and their quality of life.<\/jats:p>","DOI":"10.1111\/j.1743-7563.2012.01525.x","type":"journal-article","created":{"date-parts":[[2012,4,24]],"date-time":"2012-04-24T11:26:41Z","timestamp":1335266801000},"page":"132-144","source":"Crossref","is-referenced-by-count":20,"title":["Management of sunitinib adverse events in renal cell carcinoma patients: The Asian experience"],"prefix":"10.1111","volume":"8","author":[{"given":"Aiping","family":"ZHOU","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,4,24]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.3322\/canjclin.55.2.74"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyq127"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.1293"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70162-7"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.5145"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-009-1170-y"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1359-6349(09)71451-X"},{"key":"e_1_2_5_9_2","doi-asserted-by":"crossref","first-page":"e15107","DOI":"10.1200\/jco.2010.28.15_suppl.e15107","article-title":"Sunitinib for unselected Korean patients with advanced renal cell carcinoma: A comparable efficacy with different toxicity profiles [Abstract]","volume":"28","author":"Kim H","year":"2010","journal-title":"J Clin Oncol"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyq073"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2009.41.2.67"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.4111\/kju.2010.51.7.450"},{"key":"e_1_2_5_13_2","first-page":"375","article-title":"Clinical study of sunitinib in the treatment of metastatic renal clear cell carcinoma: a single center 23 cases experience","volume":"48","author":"Li XS","year":"2010","journal-title":"Chin J Surg"},{"key":"e_1_2_5_14_2","first-page":"300","article-title":"Preliminary clinical study results of sunitinib in patients with metastatic renal cell carcinoma","volume":"31","author":"Hu XY","year":"2010","journal-title":"Chin J Urol"},{"key":"e_1_2_5_15_2","first-page":"304","article-title":"Efficacy and safety of sunitinib in the treatment of metastatic renal cell carcinoma","volume":"31","author":"Zeng SL","year":"2010","journal-title":"Chin J Urol"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyp146"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyq146"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa065044"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-1893"},{"issue":"8","key":"e_1_2_5_20_2","first-page":"913P","article-title":"Clinical outcome of Asian vs non\u2010Asian patients with metastatic renal cell carcinoma (mRCC) with continuous once\u2010daily dosing of sunitinib as first\u2010line therapy [Abstract]","volume":"21","author":"Barrios CH","year":"2010","journal-title":"Ann Oncol"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2007.07.030"},{"issue":"7","key":"e_1_2_5_22_2","doi-asserted-by":"crossref","first-page":"LBA308","DOI":"10.1200\/jco.2011.29.7_suppl.lba308","article-title":"Randomized phase II multicenter study of the efficacy and safety of sunitinib on the 4\/2 versus continuous dosing schedule as first\u2010line therapy of metastatic renal cell carcinoma: Renal EFFECT Trial [Abstract]","volume":"29","author":"Motzer RJ","year":"2011","journal-title":"J Clin Oncol"},{"key":"e_1_2_5_23_2","doi-asserted-by":"crossref","first-page":"4524","DOI":"10.1200\/jco.2010.28.15_suppl.4524","article-title":"The impact of body mass index (BMI) and body surface area (BSA) on treatment outcome to vascular endothelial growth factor (VEGF)\u2010targeted therapy in metastatic renal cell carcinoma: results from a large international collaboration [Abstract]","volume":"28","author":"Choueiri TK","year":"2010","journal-title":"J Clin Oncol"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6604456"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00109-011-0737-3"},{"key":"e_1_2_5_26_2","unstructured":"Sunitinib package insert. [cited 11 Dec 2010]. Available from:http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/021938s13s17s18lbl.pdf."},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2008-0131"},{"key":"e_1_2_5_28_2","unstructured":"National Cancer Institute (NCI).Common terminology criteria for adverse events (CTCAE): version 4.0. [updated 14 June 2010 cited 23 January 2012]. Available at:http:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03_2010\u201006\u201014_QuickReference_5x7.pdf."},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.1177\/42.11.7523489"},{"key":"e_1_2_5_30_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.02.2194"},{"key":"e_1_2_5_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(05)70243-6"},{"issue":"18","key":"e_1_2_5_32_2","doi-asserted-by":"crossref","first-page":"4594","DOI":"10.1200\/jco.2006.24.18_suppl.4594","article-title":"Bevacizumab, erlotinib, and imatinib in the treatment of patients with advanced renal cell carcinoma: update of a multicenter phase II trial","volume":"24","author":"Thompson DS","year":"2006","journal-title":"J Clin Oncol"},{"key":"e_1_2_5_33_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djq091"},{"key":"e_1_2_5_34_2","first-page":"S41","article-title":"Sunitinib therapy for metastatic renal cell carcinoma: recommendations for management of side effects","volume":"1","author":"Kollmannsberger C","year":"2007","journal-title":"Can Urol Assoc J"},{"key":"e_1_2_5_35_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jhh.1001057"},{"key":"e_1_2_5_36_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.0000103630.72812.10"},{"key":"e_1_2_5_37_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.289.18.2363"},{"key":"e_1_2_5_38_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdn713"},{"key":"e_1_2_5_39_2","doi-asserted-by":"publisher","DOI":"10.1291\/hypres.28.147"},{"key":"e_1_2_5_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2010.01.003"},{"key":"e_1_2_5_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2009.11.001"},{"key":"e_1_2_5_42_2","doi-asserted-by":"publisher","DOI":"10.1080\/02841860903229124"},{"key":"e_1_2_5_43_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdp073"},{"key":"e_1_2_5_44_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605366"},{"key":"e_1_2_5_45_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6604497"},{"key":"e_1_2_5_46_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2007-0586"},{"key":"e_1_2_5_47_2","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2006.0308"},{"key":"e_1_2_5_48_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djk008"},{"key":"e_1_2_5_49_2","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.K10E-130"},{"key":"e_1_2_5_50_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-010-0627-2"},{"key":"e_1_2_5_51_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-009-1213-4"},{"key":"e_1_2_5_52_2","article-title":"Hypertension (HTN) as a biomarker of efficacy in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with sunitinib [Abstract]","author":"Rini BI","year":"2010","journal-title":"ASCO"},{"key":"e_1_2_5_53_2","doi-asserted-by":"publisher","DOI":"10.3109\/0284186X.2010.543696"},{"key":"e_1_2_5_54_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2010-0263"}],"container-title":["Asia-Pacific Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1743-7563.2012.01525.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1743-7563.2012.01525.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T01:05:42Z","timestamp":1697418342000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1743-7563.2012.01525.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4,24]]},"references-count":53,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["10.1111\/j.1743-7563.2012.01525.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1743-7563.2012.01525.x","archive":["Portico"],"relation":{},"ISSN":["1743-7555","1743-7563"],"issn-type":[{"value":"1743-7555","type":"print"},{"value":"1743-7563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,4,24]]}}}